Depression is a common mental health condition and a leading cause of disability worldwide. The World Health Organization estimates that approximately 322 million people experienced depression in 2023 [1]. Depression can affect relationships, work, physical health, and overall quality of life.
Depression was once commonly explained as a disorder caused primarily by imbalances in neurotransmitters such as serotonin, dopamine, and norepinephrine. Researchers now understand it as a heterogeneous condition involving interactions among psychological, social, genetic, nervous, immune, endocrine, and metabolic factors.
One area receiving increasing attention is the microbiota-gut-brain axis: the bidirectional communication network connecting the gastrointestinal tract and the central nervous system. The gut microbiota includes bacteria, viruses, fungi, archaea, and other microorganisms living in the digestive tract. These organisms help metabolize food components, interact with the immune system, produce vitamins and other compounds, and generate metabolites that can affect human physiology [2].
Studies have found differences in the gut microbiota of some people with depression compared with people without depression [3,4]. However, these findings do not prove that dysbiosis causes depression, and researchers have not identified a single microbial profile that can diagnose the condition. The relationship is likely bidirectional: diet, stress, sleep, medication use, illness, and depression itself may all influence the microbiome.
What Is the Microbiota-Gut-Brain Axis?
The gut and brain communicate continuously through overlapping neural, immune, endocrine, and metabolic pathways. This network allows signals originating in the digestive system to affect the brain, while stress and emotional states can alter gastrointestinal motility, secretion, permeability, and microbial conditions [2].
Important communication routes include:
- Neural signaling through the vagus nerve, enteric nervous system, and spinal pathways
- Immune mediators, including cytokines
- Hormonal and stress-response pathways, including the hypothalamic-pituitary-adrenal axis
- Microbial metabolites, including short-chain fatty acids and compounds derived from bile acids and amino acids
These systems interact rather than functioning as four separate channels. A microbial metabolite, for example, may affect immune cells, intestinal barrier function, endocrine signaling, and neural activity at the same time.
The Vagus Nerve: One Route Between the Gut and Brain
The vagus nerve is an important neural pathway connecting the brain with the heart, lungs, and digestive tract. Approximately 80% of its fibers are afferent, meaning they carry sensory information from the body toward the brain [5]. This percentage applies to the vagus nerve broadly, not exclusively to signals traveling from gut microbes.
Microorganisms do not usually communicate with vagal endings by directly contacting them. Instead, microbial metabolites and signals can interact with epithelial, enteroendocrine, enteric neural, and immune cells, which may then influence vagal activity [2,5].
Animal studies provide some of the clearest evidence that the vagus nerve can mediate microbiome-related behavioral effects. Certain probiotic interventions have altered anxiety- or depression-like behaviors in rodents, and some effects disappeared after vagal signaling was disrupted [6,7]. These experiments help establish biological plausibility, but rodent behavior and controlled laboratory microbiomes do not fully reproduce human depression.
Intestinal Barrier Function, Immunity, and Inflammation
The gastrointestinal tract contains extensive immune tissue and represents one of the body's largest interfaces with the external environment [8]. A healthy intestinal barrier helps control which substances pass from the gut lumen into the circulation while permitting nutrient absorption and communication with immune cells.
Microbial composition and activity can influence this barrier. In some settings, altered microbiota, infection, diet, medication use, or inflammation may increase intestinal permeability. This is sometimes called “leaky gut,” although increased intestinal permeability is the more precise medical term.
If microbial components such as lipopolysaccharide enter the circulation in greater amounts, they may promote immune signaling. Cytokines and other inflammatory mediators can communicate with the brain through blood-brain barrier interfaces, endothelial and immune cells, neural pathways, and brain regions that monitor circulating signals. The process is more complex than inflammatory molecules simply passing freely into the brain.
Inflammation is associated with depression in a subset of people, but it is not present in every case and is not specific to depression [9]. Evidence that gut-derived inflammation directly causes major depressive disorder in humans remains incomplete. For a closer look at this broader pathway, read The Role of Inflammation and Cytokines in Depressive Symptoms.
Inflammation may also affect tryptophan metabolism. Immune signaling can increase activity in the kynurenine pathway, changing the balance of metabolites made from tryptophan. Some kynurenine metabolites may be protective, whereas others, including quinolinic acid, can promote excitatory and oxidative stress under certain conditions [9]. This pathway is being studied as one possible link among immunity, the microbiome, cognition, and mood.
What Microbiome Studies Find in Depression
Researchers have compared stool samples from people with major depressive disorder with samples from control groups. Many studies report differences in the relative abundance of particular bacterial groups or in predicted microbial functions [3,4].
However, the results are highly heterogeneous. Differences in geography, diet, age, medication use, sequencing methods, diagnostic criteria, and other health conditions make studies difficult to compare. Findings on alpha diversity, a measure of diversity within an individual sample, are also inconsistent. Some studies report lower diversity in depression, while others find no difference or a different pattern [3,4].
For this reason, there is currently no validated stool test that can diagnose depression or determine its best treatment. Terms such as dysbiosis describe a disrupted or altered microbial ecosystem, but there is no single universal definition of a healthy microbiome.
Experiments in which microbiota from people with depression are transferred to germ-free or microbiota-depleted animals have sometimes produced depression-like behavioral and metabolic changes. These findings support the possibility of a contributory role, but they do not show that the same transfer effects occur in humans or that the microbiome acts independently of other factors.
Can Gut Microbes Produce Neurotransmitters?
Some gut microorganisms can produce or metabolize compounds that also function as neurotransmitters in humans, including GABA, dopamine, norepinephrine, acetylcholine, and serotonin-related molecules [10]. This does not mean that the microbiome directly supplies the brain with these neurotransmitters.
Most neurotransmitters made in the gut do not cross the blood-brain barrier in meaningful amounts. Instead, they may act locally within the gut, affect enteric neurons or immune cells, alter vagal signaling, or influence the availability of metabolic precursors.
Serotonin
Most of the body's serotonin is found outside the brain, with the gastrointestinal tract serving as its major peripheral source. Gut microbes and their metabolites can influence serotonin production by enterochromaffin cells [11]. Peripheral serotonin helps regulate intestinal motility, secretion, immune activity, and platelet function, but it does not cross the blood-brain barrier to replenish brain serotonin.
That distinction matters: producing more serotonin in the gut is not equivalent to producing more serotonin in the brain. Learn more in The Role of Serotonin in the Gut: From Bowel Movements to Mood.
GABA
Some strains of Lactobacillus, Bifidobacterium, and other bacteria can produce gamma-aminobutyric acid (GABA) from glutamate [12]. GABA is the principal inhibitory neurotransmitter in the adult brain, but gut-derived GABA is not known to enter the brain in substantial quantities.
Researchers are investigating whether microbial GABA can affect the enteric nervous system, immune signaling, intestinal physiology, or vagal pathways. Much of the mechanistic evidence remains preclinical, so specific GABA-producing probiotics cannot yet be assumed to improve mood in humans.
Microbial Metabolites
The microbiome may influence the brain more plausibly through metabolites than through direct delivery of neurotransmitters. Short-chain fatty acids such as acetate, propionate, and butyrate are produced when microbes ferment certain dietary fibers. These compounds can affect intestinal barrier function, immune regulation, cellular metabolism, and signaling along the gut-brain axis [2].
Microorganisms also modify bile acids and metabolize amino acids such as tryptophan and tyrosine. The resulting compounds may influence immune, endocrine, and neural pathways. Read more about these signaling molecules in How Gut Microbes Produce Chemicals That Impact Mood and Bowel Health.
Do Probiotics Improve Depression?
Randomized controlled trials have investigated probiotics, prebiotics, and synbiotics for depressive symptoms. Recent meta-analyses report improvements in some symptom scores, particularly when probiotics are used alongside standard treatment in people with diagnosed depression [13,14].
These findings are promising but require context. Trials have used different strains, combinations, doses, treatment durations, populations, and depression scales. Many studies are small, and not all trials report a benefit. Meta-analytic results also do not establish that every probiotic product has the same effect.
Evidence for changes in inflammatory markers is less consistent than evidence for changes in self-reported or clinician-rated depressive symptoms [14]. It is therefore premature to conclude that probiotics improve mood specifically by reducing inflammation.
No probiotic regimen is currently an established replacement for psychotherapy, antidepressant medication, or other indicated care. People being treated for depression should discuss supplements with a qualified healthcare professional, particularly if they are immunocompromised, seriously ill, pregnant, or taking medications.
Psychobiotics: A Promising but Developing Field
The term psychobiotic originally referred to live microorganisms that might provide mental health benefits. Its use has broadened in some literature to include prebiotics and other microbiome-targeted dietary strategies [15,16].
Approaches being studied include:
- Specific probiotic strains or multi-strain combinations
- Prebiotic fibers that support selected microorganisms
- Synbiotics combining probiotics and prebiotics
- Fermented foods and high-fiber dietary patterns
- Microbial metabolites or postbiotics
These categories are not interchangeable. Benefits observed with one strain, dose, or intervention cannot automatically be applied to another. Personalized approaches are of interest because baseline microbiomes and responses vary widely, but validated methods for matching an individual to a psychobiotic treatment do not yet exist.
Supporting the Microbiome Without Overpromising
A varied diet containing fiber-rich plant foods can supply substrates used by gut microbes, while fermented foods can introduce microbial products and, in some cases, live organisms. One randomized dietary study found that a high-fermented-food diet increased microbiota diversity and reduced several inflammatory markers, whereas a high-fiber diet altered microbial function but did not increase diversity over the short study period [17]. This illustrates why broad claims such as “more fiber always increases diversity” should be avoided.
Regular physical activity, adequate sleep, stress management, avoiding smoking, and using antibiotics only when medically appropriate may also support general and gastrointestinal health. These habits can affect mood through many pathways beyond the microbiome.
There is no single diet, food, or supplement proven to create an ideal microbiome or treat depression by itself. Persistent depressive symptoms, loss of interest, major changes in functioning, or thoughts of self-harm warrant professional care. In an immediate crisis, contact local emergency services or a crisis support service.
Conclusion
The microbiota-gut-brain axis offers a useful framework for understanding how digestive, immune, metabolic, and nervous systems communicate. Human studies associate depression with microbiome differences, while animal experiments and mechanistic research show several plausible pathways involving the vagus nerve, immune signaling, barrier function, and microbial metabolites.
At the same time, the evidence does not support reducing depression to an unhealthy gut or a missing bacterial strain. Depression can also change eating, sleep, activity, medication use, and gastrointestinal function, all of which may alter the microbiome. Cause and effect are therefore difficult to separate.
Probiotics and other microbiome-targeted interventions may eventually become useful components of personalized depression care. For now, they are best viewed as an emerging adjunct to established treatment rather than a substitute for it.
References
[1] World Health Organization. Depressive disorder (depression). 2026. https://www.who.int/news-room/fact-sheets/detail/depression.
[2] J.F. Cryan, K.J. O'Riordan, C.S.M. Cowan, et al. The microbiota-gut-brain axis. Physiological Reviews. 2019;99:1877–2013. https://doi.org/10.1152/physrev.00018.2018.
[3] S.-K.K. Lin, H.-C. Chen, I.-M. Chen, et al. Dysbiosis and depression: A study of gut microbiota alterations and functional pathways in antidepressant-naïve mood disorder patients. Translational Psychiatry. 2025;15:290. https://doi.org/10.1038/s41398-025-03521-1.
[4] Y. Cao, Y. Cheng, W. Pan, et al. Gut microbiota variations in depression and anxiety: A systematic review. BMC Psychiatry. 2025;25:443. https://doi.org/10.1186/s12888-025-06871-8.
[5] Y. Han, B. Wang, H. Gao, et al. Vagus nerve and underlying impact on the gut microbiota-brain axis in behavior and neurodegenerative diseases. Journal of Inflammation Research. 2022;15:6213–6230. https://doi.org/10.2147/JIR.S384949.
[6] H. Wang, I.-S. Lee, C. Braun, P. Enck. Effect of probiotics on central nervous system functions in animals and humans: A systematic review. Journal of Neurogastroenterology and Motility. 2016;22:589–605. https://doi.org/10.5056/jnm16018.
[7] C. Mindus, J. Ellis, N. Van Staaveren, A. Harlander-Matauschek. Lactobacillus-based probiotics reduce the adverse effects of stress in rodents: A meta-analysis. Frontiers in Behavioral Neuroscience. 2021;15:642757. https://doi.org/10.3389/fnbeh.2021.642757.
[8] S.P. Wiertsema, J. van Bergenhenegouwen, J. Garssen, L.M.J. Knippels. The interplay between the gut microbiome and the immune system in the context of infectious diseases throughout life and the role of nutrition in optimizing treatment strategies. Nutrients. 2021;13:886. https://doi.org/10.3390/nu13030886.
[9] R. Troubat, P. Barone, S. Leman, et al. Neuroinflammation and depression: A review. European Journal of Neuroscience. 2021;53:151–171. https://doi.org/10.1111/ejn.14720.
[10] L.M.T. Dicks. Gut bacteria and neurotransmitters. Microorganisms. 2022;10:1838. https://doi.org/10.3390/microorganisms10091838.
[11] N. Terry, K.G. Margolis. Serotonergic mechanisms regulating the gastrointestinal tract: Experimental evidence and therapeutic relevance. Handbook of Experimental Pharmacology. 2017;239:319–342. https://doi.org/10.1007/164_2016_103.
[12] J.D. Braga, M. Thongngam, T. Kumrungsee. Gamma-aminobutyric acid as a potential postbiotic mediator in the gut-brain axis. npj Science of Food. 2024;8:16. https://doi.org/10.1038/s41538-024-00253-2.
[13] A. Zandifar, R. Badrfam, M. Mohammaditabar, et al. The effect of prebiotics and probiotics on levels of depression, anxiety, and cognitive function: A meta-analysis of randomized clinical trials. Brain and Behavior. 2025;15:e70401. https://doi.org/10.1002/brb3.70401.
[14] H.N. Shakir Shakir, A.J. Alias-Castillo, D. Bertini-Pérez, et al. Effectiveness of probiotic supplementation in managing depressive symptoms and inflammatory status in patients with depression: A systematic review and meta-analysis. Clinical Nutrition. 2026;58:106554. https://doi.org/10.1016/j.clnu.2025.106554.
[15] A. Śliwka, M. Polak-Berecka, K. Zdybel, A. Zelek-Molik, A. Waśko. Psychobiotics in depression: Sources, metabolites, and treatment—A systematic review. Nutrients. 2025;17:2139. https://doi.org/10.3390/nu17132139.
[16] R. Sharma, D. Gupta, R. Mehrotra, P. Mago. Psychobiotics: The next-generation probiotics for the brain. Current Microbiology. 2021;78:449–463. https://doi.org/10.1007/s00284-020-02289-5.
[17] H.C. Wastyk, G.K. Fragiadakis, D. Perelman, et al. Gut-microbiota-targeted diets modulate human immune status. Cell. 2021;184:4137–4153.e14. https://doi.org/10.1016/j.cell.2021.06.019.
